Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cognition Therapeutics Inc (NQ: CGTX ) 1.880 -0.030 (-1.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cognition Therapeutics Inc < Previous 1 2 3 Next > Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC July 02, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease May 21, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update May 07, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies April 29, 2024 - Top-line Results Expected in the Second Half of 2024 - From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease April 22, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference April 02, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024 April 01, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update March 26, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering March 15, 2024 Via Investor Brand Network Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results March 15, 2024 Conference Call and Live Audio Webcast Scheduled for March 26, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock March 14, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Proposed Public Offering of Common Stock March 11, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies March 06, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to Present at the TD Cowen Health Care Conference February 26, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812 February 06, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics CEO Issues Letter to Shareholders January 04, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens November 16, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases November 15, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease November 07, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD October 27, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD October 24, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications October 16, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD September 07, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Participation in Upcoming September Conferences August 30, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update August 08, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023 August 02, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD July 11, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease July 05, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease June 28, 2023 From Cognition Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.